ATE390929T1 - Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser - Google Patents

Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser

Info

Publication number
ATE390929T1
ATE390929T1 AT00985660T AT00985660T ATE390929T1 AT E390929 T1 ATE390929 T1 AT E390929T1 AT 00985660 T AT00985660 T AT 00985660T AT 00985660 T AT00985660 T AT 00985660T AT E390929 T1 ATE390929 T1 AT E390929T1
Authority
AT
Austria
Prior art keywords
kappab
antigen
trigger
activation
immune system
Prior art date
Application number
AT00985660T
Other languages
English (en)
Inventor
Brian Foxwell
Marc Feldmann
Original Assignee
Kennedy Rheumatology Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Rheumatology Inst filed Critical Kennedy Rheumatology Inst
Application granted granted Critical
Publication of ATE390929T1 publication Critical patent/ATE390929T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00985660T 1999-12-24 2000-12-22 Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser ATE390929T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930616.9A GB9930616D0 (en) 1999-12-24 1999-12-24 Activation and inhibition of the immune system

Publications (1)

Publication Number Publication Date
ATE390929T1 true ATE390929T1 (de) 2008-04-15

Family

ID=10867023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985660T ATE390929T1 (de) 1999-12-24 2000-12-22 Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser

Country Status (12)

Country Link
US (2) US7915009B2 (de)
EP (2) EP1852123A3 (de)
JP (1) JP2003518507A (de)
CN (2) CN1254272C (de)
AT (1) ATE390929T1 (de)
AU (1) AU781496B2 (de)
CA (1) CA2394880A1 (de)
DE (1) DE60038503T2 (de)
ES (1) ES2302707T3 (de)
GB (1) GB9930616D0 (de)
NZ (1) NZ519438A (de)
WO (1) WO2001047543A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
JP2003055202A (ja) * 2001-08-15 2003-02-26 Hiroyuki Hanai 炎症性腸疾患の予防・治療剤
EP1512415A4 (de) * 2002-05-29 2005-11-09 Anges Mg Inc Decoy-zusammensetzung zur behandlung und prävention von entzündlichen erkrankungen
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
US20060257380A1 (en) * 2002-09-19 2006-11-16 Inst.Nat. De La Sante Et De La Recherche MED Use of sirnas for gene silencing in antigen presenting cells
EP2557164A1 (de) 2003-02-18 2013-02-13 Kevin M. Slawin Induzierte Aktivierung ein dendritischen Zellen
WO2004101745A2 (en) * 2003-05-08 2004-11-25 Beth Israel Deaconess Medical Center, Inc. NOVEL REGULATORY MECHANISMS OF NF-kappaB
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
WO2007001487A2 (en) * 2005-06-23 2007-01-04 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US20080311552A1 (en) * 2005-09-20 2008-12-18 London Health Sciences Centre Research, Inc. Use of Sirnas in Organ Storage/Reperfusion Solutions
JP5199878B2 (ja) 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
CN101240271B (zh) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll样受体调节性寡核苷酸及其用途
EP3590503A1 (de) 2006-10-12 2020-01-08 The University of Queensland Zusammensetzungen und verfahren zur modulation von immunreaktionen
AU2007310946B2 (en) * 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CN103889461B (zh) * 2011-07-18 2016-11-09 肯塔基大学研究基金会 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014236726A1 (en) 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
ES2761280T3 (es) * 2013-09-12 2020-05-19 Icahn School Med Mount Sinai Métodos de producción de animales transgénicos con receptores de células T que son específicos de una proteína fluorescente
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
US20150342961A1 (en) * 2014-06-03 2015-12-03 Hai-Hui Xue Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
WO2016036746A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
LT3976597T (lt) 2019-05-31 2024-10-10 Janssen Pharmaceutica Nv Nf-κb indukuojančios kinazės mažos molekulės inhibitoriai

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
ES2174822T3 (es) 1989-11-03 2002-11-16 Immulogic Pharma Corp Una proteina felina reactiva con celulas t humanas (trfp) aislada de polvo domestico y usos para la misma.
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
ATE163046T1 (de) 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5405941A (en) 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US20020106370A1 (en) 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
US5597898A (en) * 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
WO1997001340A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal mast cell stabilizers
EP0779361A3 (de) * 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Verkürzte Form von Kappa B Inhibitor-Protein, rekombinanter Herstellung und Verwendung
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
ES2315435T3 (es) * 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
CA2263835C (en) * 1996-08-26 2012-02-21 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
EP2003203A1 (de) 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6924308B1 (en) * 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US5952483A (en) * 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
EP0897009A3 (de) * 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 Polypeptide
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子ＮＦ−κＢ活性化阻害剤
GB9719238D0 (en) 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5965421A (en) 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
EP1119618A2 (de) * 1998-02-19 2001-08-01 Peter Bromley Stress-promoter-kontrolle der therapeutischen genen in gentherapie: zusammensetzungen und verfahren
CA2328483A1 (en) * 1998-05-06 1999-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Inhibitors of nf-kb activation
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2000054839A2 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004522432A (ja) 2000-12-22 2004-07-29 シノヴィス・リミテッド Ｔｏｌｌ関連レセプター（ｔｒｒ）シグナル伝達の調節方法
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods

Also Published As

Publication number Publication date
CN1817367A (zh) 2006-08-16
WO2001047543A2 (en) 2001-07-05
US20030153518A1 (en) 2003-08-14
AU2206201A (en) 2001-07-09
CN100563707C (zh) 2009-12-02
NZ519438A (en) 2004-03-26
GB9930616D0 (en) 2000-02-16
CA2394880A1 (en) 2001-07-05
CN1434718A (zh) 2003-08-06
JP2003518507A (ja) 2003-06-10
EP1852123A3 (de) 2008-09-10
EP1244466B1 (de) 2008-04-02
CN1254272C (zh) 2006-05-03
AU781496B2 (en) 2005-05-26
US20080124322A1 (en) 2008-05-29
ES2302707T3 (es) 2008-08-01
WO2001047543A3 (en) 2002-01-17
DE60038503T2 (de) 2009-04-30
DE60038503D1 (de) 2008-05-15
EP1852123A2 (de) 2007-11-07
EP1244466A2 (de) 2002-10-02
US7915009B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
ATE390929T1 (de) Aktivierung des immunsystems durch einen antigen und einen nf-kappab auslöser
ATE357511T1 (de) Dipeptidylpeptidasen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20020348L (no) Peptid acceptor ligeringsmetoder
ES2114692T3 (es) Reaccion en ciclos magneticos.
ATE287402T1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
BR0208105A (pt) Inibidores de metaloproteinase
WO2003050260A3 (en) Streptavidin expressed gene fusions and methods of use thereof
BR9800931A (pt) Processo de inibidor de polimerização
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
WO2001088124A3 (en) Method and reagent for the inhibition of erg
DE60139959D1 (de) Nukleinsäureadjuvantien
DK0845034T3 (da) Peptid med pronociceptive egenskaber
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
NZ515041A (en) Nucleic acid immunization
NO20033921L (no) Inhibitor av monoaminopptak
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
ES2188545T3 (es) Polimeros que contienen aminoacidos basicos alcoxilados, concensados, y procedimiento para su obtencion.
FI20030851A7 (fi) CARD-geenistä ylävirtaan olevia sekvenssejä, niitä sisältäviä vektoreita ja niiden käyttöjä
WO2001059108A3 (en) Inhibitors of apoptosis
WO2003010309A1 (en) Oligonucleotides for detecting tubercle bacillus and method therefor
WO2003004678A3 (en) Novel receptors
WO2003031470A3 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
WO2002046378A3 (en) Alternative pol k nucleotide and amino acid sequence and methods for using
EP1180525A4 (de) Hemmerprotein der transkriptionsaktivierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties